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Available online at www.sciencedirect.comRespiratory syncytial virus (RSV) is the most important cause of
infantile bronchiolitis and a major pathogen in elderly and
immunosuppressed persons. Although RSV shows limited
antigenic diversity, repeated infections occur throughout life.
Vaccine development has been delayed by poor
immunogenicity, production issues and the fear of causing
enhanced disease. T cells assist in viral clearance, but immune
regulation serves to limit these responses and to prevent the
exaggerated inflammatory response to RSV infection seen in
children with bronchiolitis. Severe RSV disease can therefore
be regarded as a dysregulated response to an otherwise trivial
infection. Further insights into the role of T cells (including Th17)
are needed to enable the rational design of safe, effective
vaccines and novel treatments.
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Introduction
Respiratory syncytial virus (RSV) is a leading cause of
morbidity in infants, and is increasingly appreciated as a
major cause of illness and death in susceptible adults.
Globally, it is estimated that there are 33.8 million new
episodes of RSV infection per year, leading to around 3.4
million hospital admissions and up to 199 000 deaths
(99% of which occur in the developing world) [1]. While
healthy young adults generally only suffer common cold
symptoms and are at low risk of severe disease, RSV has
an unusual ability to re-infect. Approximately 10% of
adults suffer repeat RSV infection each year, accounting
for up to 5% of admissions for community acquired
pneumonia at an annual cost of $680 million in the
USA for in-patient treatment alone. Although RSV causes
Open access under CC BY-NC-SA license.Current Opinion in Virology 2013, 3:468–474 a vast burden of disease, its name is virtually unknown by
the public, or by most policymakers.
Unlike many other viruses, infection with RSV does not
induce durable protective immunity. Although it is clear
that most severe disease occurs during primary infantile
infection, symptomatic upper respiratory tract infections
occur throughout life. While infection with a given strain
of influenza may protect against symptomatic disease
caused by that same strain for up to seven years, even
healthy adults can be repeatedly infected with an iden-
tical RSV at as little as two month intervals.
Antibody and vaccines
The reasons underlying this incomplete immunity remain
unclear. Antibody can protect, since passive immunisation
with the humanised anti-RSV F protein monoclonal pali-
vizumab (SynagisTM) reduces the risk of hospitalisation for
bronchiolitis in high-risk infants by around 50% [2]. How-
ever, even individuals with the highest levels of natural
anti-RSV neutralising antibodies are not reliably protected
against nasal infection and some individuals with low
antibody titres are resistant [3], suggesting that anti-
body-independent immunity is also important. Conver-
sely, baseline antibody titres are well maintained in elderly
adults despite the fact that disease is more frequent and
severe in this population. Multiple infections are required
for accumulation of these antibodies, as levels induced
acutely also fall rapidly with a 4-fold or greater drop in the
majority of adults by one year post-infection [4].
Thus, defects in the humoral response are probably partly
responsible for the phenomenon of incomplete immu-
nity. However, it is not clear whether this is due to an
intrinsic B cell defect, due to failure of T cell help or
caused by some as yet unknown influence of the virus on
the immune system. In mice, the antibody response to
neonatal RSV infection is weaker than that in adult life
and is helper T cell independent. By contrast, the stron-
ger adult response does depend on helper T cells. Inter-
estingly, depletion of Natural Killer cells or CD8+ T cells
during neonatal RSV infection boosts anti-RSV antibody
responses. Both these cell types are major sources of IFN-
g and blocking IFN-g causes similar effects. By contrast,
providing additional IFN-g by recombinant cytokine
expression reduces antibody responses [5]. Improved
understanding of the factors determining the generation
of protective antibody is clearly important in the devel-
opment of effective vaccines for the neonate.
In young children, particularly preterm babies and neo-
nates, RSV may cause bronchiolitis, characterised by anwww.sciencedirect.com
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oedema, cellular infiltration and tissue necrosis. It
remains uncertain why some individuals are at higher
risk of this exaggerated immune response. Formalin-
inactivated RSV vaccine (FI-RSV), tested in children
in the 1960s, not only failed to protect, but also induced
unexpectedly severe disease in young children during
subsequent natural infection. In those trials, FI-RSV
vaccinees suffered an 80% hospitalisation rate following
natural infection with RSV and two of those children died.
Infantile bronchiolitis and lung disease augmented by FI-
RSV both seem to represent an uncontrolled immunolo-
gically mediated tissue damage, though differing signifi-
cantly in the type of pathology that is seen.
The development of an effective and safe vaccine that
protects against RSV has long been constrained by these
two factors: poor immune protection and heightened
immunopathology. As our understanding of the mechan-
isms behind these opposing factors in RSV has increased,
it has become clear that more subtle, less empirical
approaches to vaccine design will be required to over-
come these problems. It is also increasingly obvious that
the effector and regulatory capabilities of T cells must be
balanced in order to induce a coordinated adaptive
response capable of providing long-term protective
immunity (Figure 1).
T cells in viral clearance and protection
T cells are believed to play an essential role in clearance
of RSV from the lungs. In the BALB/c mouse, up to 40%
of CD8+ T cells infiltrating the lung may be specific for an
epitope from the M2 protein at the peak of infection [6].
Early studies in athymic nude or irradiated mice showed
that persistent infection with prolonged RSV shedding
could be cleared by adoptive transfer of memory T cells
from previously primed animals [7]. In BALB/c mice
depleted of CD4+ or CD8+ T cells, both T cell subsets
play a role in shortening the duration of RSV shedding [8].
Conversely, stimulation of epitope-specific CD8+ T cells
using peptide immunisation of HLA-A*0201 transgenic
mice ameliorates disease and improves viral control [9].
Immunisation using peptide-loaded dendritic cells (DCs)
from the closely related pneumonia virus of mice confers
partial protection against subsequent RSV challenge
[10]. Similar findings have been observed in other
animal models such as RSV infection (e.g. calves) in
which depletion of CD8+ T cells delays viral clearance.
In human observational studies, T cells are also impli-
cated in viral clearance. In children with severe infection,
CD8+ antigen-specific T cells accumulate in the periph-
eral blood and airways, peaking at around nine days after
symptom onset [11]. These display an activated pheno-
type, but their abundance does not correlate with disease
severity. In studies of adults, numbers of activated CD4+
and CD8+ T cells do correlate with disease severitywww.sciencedirect.com [12]. A role for T cells in viral clearance is also implied
by a prospective study examining children under the age
of five, in which individuals immunocompromised due to
chemotherapy or with primary immunodeficiencies
affecting T cell function were shown to suffer more
severe disease and shed virus at higher levels for several
months, compared with 7–21 days in normal children [13].
This is also true of adult bone marrow transplant recipi-
ents. The increased frequency and risk of severe RSV
disease seen in elderly adults may similarly be related to
the lower numbers and decreased proliferative and func-
tional capacity of IFN-g producing RSV F-protein
specific T cells seen in that population [14].
However, despite these data suggesting the apparent
importance of T cells, it remains to be seen whether
measuring T cell responses provides an additional corre-
late of protection in man that might be of use in vaccine
development.
Modulation of T cell activity by RSV
The relationship between T cell numbers or function and
protection from RSV re-infection may not be simple, and
is complicated by checks and balances in the immune
system. Although some individuals are protected from
RSV re-infection in the absence of high levels of neu-
tralising antibody, most are not [3]. In a prospective study
of infants with RSV bronchiolitis, virus-specific T cell
responses could be demonstrated during the convalescent
phase, but these did not correlate with protection from
infection the following year and were not boosted on
secondary infection [15]. It is now increasingly clear that
RSV takes advantage of several mechanisms that lead to
the modulation of T cell function in order to permit these
productive re-infections.
Mechanisms for immune evasion are common in many
pathogens that have undergone prolonged co-evolution
with their hosts. A number of RSV proteins have therefore
been implicated in immune modulation. For example,
both bovine and human RSV nonstructural proteins NS1
and NS2 have been shown to suppress the production of
type I interferons by epithelial cells [16]. In addition,
modulation of effector functions may occur as a con-
sequence of changes in the pulmonary microenviron-
ment, which is generally maintained in a relatively
anti-inflammatory state [6,17]. CD8+ T cells from
infected murine lungs (but not spleen) are impaired in
their cytolytic ability and capacity to produce IFN-g [18].
In the RSV-infected airway, feedback mechanisms such
as the upregulation of PD-1/PD-L1 are activated and
inhibit CD8+ T cells in order to prevent immune-related
tissue damage [19]. It is probably that these mechanisms
all contribute to impaired RSV-specific T cell immunity.
Recently, the effect of RSV on interactions between T
cells and DCs has come under scrutiny. DCs are majorCurrent Opinion in Virology 2013, 3:468–474
470 Role of T cell immunity in virus infections
Figure 1
RSV
Respiratory epithelium
Inhibitory
signals e.g.
PD-1/PD-L1
Type I IFNs
Antigen
presentation
Viral
clearance
Immunomodulation
B cell help
Infection
Immunopathology
DC CD8
Th1
Tfh
Th2
Th17
Treg
γδ
Current Opinion in Virology
The role of T cells in RSV clearance, protective immunity and immunopathology. RSV infects respiratory epithelial cells but impairs innate immune
responses by inhibiting type I interferons and upregulating inhibitory molecules in the lung. Direct infection of dendritic cells also causes dysregulation
of antigen presentation, leading to impaired T cell function, reduced viral clearance and memory formation. The T cell response is also skewed towards
T cell subsets that enhance immunopathology but which may be limited by regulatory T cells. Proposed mechanisms by which RSV deranges the T cell
response are shown in red text.
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face between the innate and adaptive arms of the immune
system. In vitro, RSV can infect DCs and undergo active
replication [20,21]. In the mouse, conventional and pla-
macytoid DCs do migrate to the lung during RSV in-
fection and transport antigen to the draining lymph nodes
[22]. However, despite undergoing phenotypic matu-
ration, RSV-infected human DCs are poor inducers of
T cell effector function in vitro. Compared with human
metapneumovirus, they significantly impair CD4+ T cell
proliferation [20] and in several different models, they
have been shown to inhibit the production of cytokines,
including IFN-g [23].
The mechanisms underlying this phenomenon remain
unclear. The ability of DCs to carry antigen for presen-
tation to T cells may allow F protein to directly inhibit T
cell proliferation. Some strains of RSV may also interfere
with the production of type I interferons by plasmacytoid
DCs [24], although this conflicts with other studies that
suggest that IFN-a and IFN-l produced by monocyte-
derived DCs infected with live RSV suppress CD4+ T
cell proliferation [25]. In vitro culture of human T cells
with DCs infected with RSV deletion mutants lacking
NS1 protein has demonstrated increased proliferation of
CD103+ mucosa-homing CD8+ T cell with concurrent
increase in Th17 and Th2-like CD4+ T cells unrelated to
the effect of NS1 on type I interferons [26]. Finally, it
has been proposed that RSV infection of DCs renders
them unable to activate T cells (even causing those T
cells to be refractory to further stimulation) due to failure
of assembly of the immunological synapse [27]. This may
also be affected by the differential expression on DCs of
co-stimulatory molecules such as CD40 and OX40L in
response to individual RSV proteins and their down-
stream effects on cytokine production by T cells [28].
The role of T cells in RSV immunopathology
Despite the importance of T cells in viral clearance,
cellular immunity is also paradoxically associated with
increased severity of disease. In the mouse model,
depletion of CD8+ (and to a lesser extent CD4+) T cells
has been shown to reduce weight loss following RSV
infection despite delaying clearance of virus [7,8].
Following the events surrounding the failure of FI-RSV,
major efforts were made to understand the resultant
vaccine-enhanced disease. More severely affected chil-
dren were found to have increased pulmonary inflam-
mation and eosinophilia, thus implicating an
overexuberant immune response as the cause. It was noted
that these features mirrored those of a CD4+ Th2 response
and therefore a potential role for T cells in regulating this
phenomenon. Although Th2 cytokines are not consistently
found in children with bronchiolitis [29,30], FI-RSV can
induce skewing towards a Th2 cytokine response in a
variety of animal models [31,32]. IL-27, which enhanceswww.sciencedirect.com Th1 differentiation and suppresses Th2 and Th17-type
responses in mice, can prevent vaccine-enhanced inflam-
mation if overexpressed [33]. Using recombinant vaccinia
viruses expressing individual RSV proteins, it was found
that while both F and N protein induce inflammatory
infiltrates in the lung, only G protein causes pulmonary
eosinophilia [34]. Furthermore, T cell responses made by
mice against the G protein are directed against a dominant
MHC class II-restricted epitope; by comparison, F induces
both CD4+ and CD8+ T cell responses [35].
The absence of a normal IFN-g producing CD8+ T cell
response may therefore be involved in skewing towards a
Th2 phenotype. This is particularly pertinent as many
vaccine candidates involve the administration of adju-
vanted RSV proteins that are expected to present prim-
arily via MHC class II and to a much lesser extent by
cross-presentation. In mice, when purified F or G
adsorbed to alum (which was also in the FI-RSV) is used
to immunise, both proteins induce a Th2 response,
suggesting that the mode of presentation or the nature
of the adjuvant may play a significant role [36]. A con-
struct in which G protein was expressed along with a
known immunodominant class I-restricted epitope
induced no pulmonary eosinophilia, implying that the
co-expansion of antigen-specific CD8+ T cells abrogated
the Th2 response [37]. This has been further tested in the
BALB/c mouse in which stimulation of epitope-specific
CD8+ T cells using a class I-restricted peptide vaccine
mixture protected against the immunopathologic features
observed during infection with RSV line 19 [38]. RSV-
specific CD8+ T cells therefore seem to play an essential
role both in viral clearance and the generation of a
balanced T cell response in spite of their demonstrated
potential for unwanted tissue damage.
Other T cell subsets have been implicated in the immu-
nopathology seen during RSV infection. These include
nonclassical T cells, such as gd T cells, seen in BALB/c
mice after priming with recombinant vaccinia expressing
F protein followed by RSV challenge [39]. Increased gd T
cell numbers had a minor effect on viral clearance but are
associated with increased disease severity. Interestingly,
these cells make Th1-like cytokines early post infection,
but more IL-4, IL-5 and IL-10 at later time-points.
It has more recently been shown that Th17 cells may also
play a role in regulating inflammation in the RSV-infected
lung. This CD4+ T cell subset is enriched at mucosal
sites and characterised by production of IL-17, a cytokine
that induces chemokine production by respiratory epi-
thelial cells and resultant leukocyte infiltration [40]. In
vitro, bronchial epithelial cells infected with RSV cause
the differentiation of peripheral blood lymphocytes to
Th2 and Th17 phenotypes [41]. In mouse models, mem-
bers of the IL-17 family are induced following RSV
infection and cause neutrophil recruitment to the airway,Current Opinion in Virology 2013, 3:468–474
472 Role of T cell immunity in virus infectionsmucus production, and impairment of viral clearance,
possibly via reduction in CD8+ T cell numbers and
function in lung and draining lymph nodes [42]. IL-17
may also be involved in airway hyper-responsiveness seen
following RSV infection via induction of tachykinin and
complement activation [43]. In humans, the role of Th17
cells remains unclear. While IL-17 has been detected in
tracheal aspirates from mechanically ventilated children
with bronchiolitis, in non-ventilated patients IL-17 peaks
later during convalescence [42,44]. It therefore remains
to be determined whether Th17 cells are involved in the
immunopathology related to RSV or during recovery.
Regulatory T cells in the modulation of RSV
immunopathology
It has recently become evident that there are sophisti-
cated and elegant systems that curtail antiviral effector
mechanisms and thus limit inflammation and tissue
damage. For T cells, these include programmed cell
death following the peak of antigen-induced proliferation
and upregulation of inhibitory molecules such as PD-1
[45]. Additionally, the control of T cell-associated auto-
immunity and immunopathology is mediated by the
regulatory T cell (Treg) subsets, the importance of which
has recently been demonstrated in RSV disease.
Tregs are essential modulators of the adaptive immune
response, making up 5–10% of CD4+ T cells in the mouse
and often (but not invariably) characterised by the expres-
sion of the transcription factor FoxP3. Absence of CD4+
FoxP3+ Treg cells in both mice and humans leads to
autoimmunity, and defective or suboptimal Treg function
during RSV infection may cause immunopathology. In
RSV-infected mice, Tregs proliferate and accumulate in
the lungs, upregulating activation markers and CTLA-4
[46]. Depletion of Tregs leads to enhanced viral clearance
but also to disease exacerbation and increased numbers of
antigen-specific IFN-g and TNF-a producing CD8+ T
cells [46,47]. Recent evidence has also implicated Tregs in
maintaining tolerance, which RSV infection in infant mice
then breaks, thus predisposing towards allergic airways
disease [48]. Conversely, increasing Tregs by adminis-
tration of preformed IL-2/anti-IL-2 immune complexes
reduces pulmonary inflammation without inhibition of
viral clearance [49].
Our recent studies demonstrate a remarkable decline of
Tregs in RSV-infected mice with vaccine-enhanced lung
disease. Passive transfer of conventional virus-specific
CD4+ T cells replicates the augmented disease, showing
that these cells are pathogenic. Moreover, selective
recruitment of Tregs into the RSV-infected airway by
inhalational administration of CCL17/22 attenuates
vaccine-enhanced disease [50].
Further details of how Tregs inhibit lung inflammation
continue to emerge, but studies in our group have shown anCurrent Opinion in Virology 2013, 3:468–474 unexpected functional requirement for granzyme B
expression by pulmonary Tregs [49]. Anti-inflammatory
cytokines such as IL-10 are also produced in abundance by
this subset and limit pulmonary inflammation [51]. It
remains to be determined whether Tregs are the primary
source [52,53].
As yet, there is no data in humans as to the role of Tregs in
modulating inflammatory responses in primary or second-
ary RSV infection. However, it does seem clear that
coordinated induction of Tregs is essential for the control
of mucosal inflammation during RSV infection. Thus,
Tregs appear to limit immunopathology in RSV disease
and may provide new opportunities for interventions to
limit inflammatory disease.
Conclusion
T cells are essential for the clearance of viral infection and
generation of protective immunity. However, infection
with RSV causes a dysregulated antiviral immune
response with impaired T cell function as well as exag-
gerated inflammation via multiple mechanisms
(Figure 1). RSV vaccine development has been hindered
by these two opposing constraints. An effective vaccine
should stimulate a balanced immune response in which T
cells assist in the generation of cytotoxic and humoral
memory responses without causing enhanced immune-
related inflammation. Our understanding of the cell types
and processes that participate in this process remains
incomplete, especially in man. Further studies that
address the role of T cells both as mediators of protection
and modulators of immunopathology are therefore
urgently required.
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